Verapamil Dosing for Tachycardia
For acute supraventricular tachycardia in adults, administer verapamil 5-10 mg (0.075-0.15 mg/kg) as a slow IV bolus over at least 2 minutes under continuous ECG and blood pressure monitoring, with a repeat dose of 10 mg (0.15 mg/kg) after 30 minutes if needed. 1
Adult Dosing Protocol
The FDA-approved dosing regimen is straightforward 1:
- Initial dose: 5-10 mg IV bolus over at least 2 minutes
- Repeat dose: 10 mg IV after 30 minutes if initial response inadequate
- Elderly patients: Administer over at least 3 minutes to minimize adverse effects
- Maintenance infusion: 0.005 mg/kg/min if sustained control needed 2
This dosing achieves approximately 60-80% conversion to sinus rhythm in supraventricular tachycardia within 10 minutes 1.
Critical Safety Considerations
Never use verapamil for wide-QRS tachycardia of unknown etiology - this is a class III contraindication that can cause life-threatening hemodynamic collapse 3, 4. In one study, 44% of patients with ventricular tachycardia who received verapamil developed severe hypotension or loss of consciousness requiring immediate cardioversion 4.
Absolute Contraindications:
- Wide-QRS tachycardia of unknown origin
- Pre-excited atrial fibrillation/flutter (WPW syndrome) - risk of ventricular fibrillation 3, 2
- Decompensated heart failure or cardiogenic shock
- Second or third-degree AV block without pacemaker
- Hypotension
Pediatric Dosing
For children, weight-based dosing is essential 1:
- Age 0-1 year: 0.1-0.2 mg/kg IV over at least 2 minutes (usual range 0.75-2 mg)
- Age 1-15 years: 0.1-0.3 mg/kg IV over at least 2 minutes (usual range 2-5 mg, maximum 5 mg)
- Repeat dose: Same dose 30 minutes later if needed (maximum 10 mg single dose for ages 1-15)
Important caveat: Traditional teaching states verapamil is contraindicated in infants due to reports of cardiovascular collapse. However, recent evidence 5 demonstrates safe use for verapamil-sensitive fascicular VT when given as a slow infusion over 10-30 minutes (not rapid push) in hemodynamically stable infants. The historical collapses occurred with rapid IV push in compromised infants.
Specific Indications by Tachycardia Type
Based on 2020 ESC guidelines 3:
Recommended for:
- Acute atrial flutter
- Chronic AVNRT (atrioventricular nodal reentrant tachycardia)
- Chronic focal atrial tachycardia
- Idiopathic fascicular ventricular tachycardia (verapamil-sensitive VT)
No longer recommended for:
- Inappropriate sinus tachycardia
- Acute management of narrow-QRS tachycardias (amiodarone/digoxin preferred by some protocols)
Monitoring Requirements
Continuous monitoring is mandatory 1:
- ECG monitoring throughout administration
- Blood pressure monitoring
- Have DC cardioversion immediately available
- Resuscitation equipment on standby
The 2016 ACC/AHA/HRS guidelines emphasize that initial use should occur in a treatment setting with full monitoring and resuscitation capabilities, though office use may be acceptable once patient response is established 2.
Drug Interactions
Verapamil significantly increases digoxin levels by 30-50% 2. If patient is on digoxin, monitor levels closely and consider dose reduction. Verapamil is a moderate CYP3A4 inhibitor and P-glycoprotein inhibitor, interacting with numerous medications including dabigatran, rivaroxaban, simvastatin, and many others 2.
Alternative Infusion Protocol
For sustained control, continuous infusion at 1 mg/min following calcium pretreatment (1 g IV) has been shown effective, with mean total dose of 20 mg required for rate control without blood pressure depression 6. However, this is not standard FDA-approved dosing and should be reserved for refractory cases under specialist guidance.